We have bought our global incubation, innovation and investment ecosystem to the UK to support and facilitate access to China for UK-based companies. Our centres in Cambridge and Newcastle join the TUS family of 100 cities and regions around the world.
In a unique partnership with Trinity College, University of Cambridge and Cambridge Science park we have invested £200m across five buildings, including the Park’s first Bio-Innovation Centre. This investment puts us at the heart of the thriving technology and innovation sector in this world-leading city.
TusPark Newcastle works with Barclays Eagle Labs at Newcastle. The space also provides both co-working spaces and support for start-up including free networking events, seminars and access to legal, accounting and intellectual property support teams to facilitate growth.
To experience for yourself what TusPark UK has to offer, please come and visit us. We would be delighted to show your around, introduce you to other innovators and entrepreneurs based in our Cambridge and Newcastle spaces and spend some time with you to understand how we might be able to support your venture.
We not only provide hot desk, office and bio-incubator space to enable young ventures to test and develop ideas but also the fundamental support services to fuel that development, including access to accelerator programmes, investor networking and business partner matching.
Find out how we can support your ideas…
As a holding corporation managing assets valued over US$30 Billion and a controlling shareholder/shareholder of over 800 enterprises, our parent company, TUS Holdings has established the world’s largest global innovations ecosystem with over 300 innovation bases that have incubated over 10,000 enterprises. As such we are uniquely positioned to enable access to investment and funding for enterprises across a range of industry sectors.
Discover more here…
Mogrify Limited (Mogrify®), a biopharmaceutical company located in Bio-Innovation Centre, announced today an additional $10 million USD closing of its Series A financing, bringing the total raised to $46 million USD in this round. The funding will support further advancement of Mogrify’s pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.Read More
We are delighted to be partnering with KPMG and Growth Works to jointly organise a workshop on fund raising, inviting Salvatore Di Maggio, Senior Manager of Growth Business at KPMG to discuss how to Find Your Way to Funding and Getting Investors Ready.Read More